- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
CTIC Market Currents
more »
-
May 10 Cell Therapeutics (CTIC +9.9%) shares spike after the company reports its Pixuvri cancer drug is approved in the EU as monotherapy to treat adults with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Pixuvri is the first approved treatment in the EU in this patient setting.
4 Comments[Healthcare, On the Move]
CTIC in Focus
more »
CTIC Related Articles
more »
CTIC News
more »
-
at MarketWatch.com (Feb 17, 2012)
-
at MarketWatch.com (Jan 30, 2012)
-
at MarketWatch.com (Dec 9, 2011)
-
at MarketWatch.com (Dec 9, 2011)
-
at MarketWatch.com (Jun 11, 2010)
CTIC Press Releases and Filings
more »
-
PR Newswire (May 10, 2012)
-
PR Newswire (Apr 20, 2012)
-
PR Newswire (Apr 19, 2012)
-
PR Newswire (Apr 19, 2012)
-
PR Newswire (Apr 18, 2012)
CTIC Latest Transcript
more »
CTIC Cramer
more »
Currently, there are no Cramer articles on CTIC.
CTIC Instablog posts
more »
CTIC vs. ETF Alternatives
Company Description
We develop, acquire and commercialize novel treatments for cancer. Our goal is to build a leading biopharmaceutical company with a diversified portfolio of proprietary cancer drugs. Our research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways... More
